Home/Pipeline/Engineered Treg Cell Therapy (SRC knockout)

Engineered Treg Cell Therapy (SRC knockout)

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

CoRegen

About CoRegen

CoRegen is a private, pre-clinical biotech leveraging a foundational discovery from the O'Malley Lab at Baylor College of Medicine. Its platform involves engineering regulatory T cells (Tregs) by knocking out a specific steroid receptor coactivator (SRC) gene, which reprograms these cells to trigger a potent and precise anti-cancer immune response, as demonstrated in extensive mouse studies. With a veteran leadership team, strong academic validation including the 2023 Cozzarelli Prize, and a partnership for manufacturing, the company is targeting an IND filing in 2025 to initiate human trials. The goal is to develop a scalable, single-infusion outpatient therapy for multiple solid tumors.

View full company profile

Therapeutic Areas

Oncology Solid Tumors

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed